1. Defining outcomes for beta cell replacement therapy: a work in progress.
- Author
-
Piemonti L, de Koning EJP, Berney T, Odorico JS, Markmann JF, Stock PG, and Rickels MR
- Subjects
- Blood Glucose analysis, C-Peptide analysis, Europe, Glycated Hemoglobin analysis, Guidelines as Topic, Humans, Hypoglycemia diagnosis, International Cooperation, Patient Satisfaction, Societies, Medical, Treatment Outcome, Islets of Langerhans Transplantation methods, Islets of Langerhans Transplantation standards, Pancreas Transplantation methods, Pancreas Transplantation standards
- Abstract
Defined outcomes for beta cell replacement therapy in the treatment of diabetes are critically needed. Progress towards the clinical acceptance of pancreas and islet transplantation has been hampered by the lack of clear definitions of functional and efficacy outcomes, as well as a lack of consistently applied glycaemic control metrics, together with poor alignment with the field of artificial insulin delivery/artificial pancreas development. To address this problem, the International Pancreas & Islet Transplant Association (IPITA) collaborated with the European Pancreas and Islet Transplant Association (EPITA) to develop a consensus for a joint statement on the definition of function and failure of beta cell replacement therapies, which is summarised in this commentary.
- Published
- 2018
- Full Text
- View/download PDF